Profound Medical (PRN.TO) Stock Price
Profound Medical Price
Revenue has compounded at 16.0% per year over the past 7 years to 10.68 M USD. Profound Medical's net margin stands at -260.4%, up from -296.0% several years earlier. Analysts set a median price target of 11.17 USD, implying 68.4% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 70% above its 52-week low.
Profound Medical stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Profound Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Profound Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Profound Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Profound Medical Price |
|---|---|
| 6/12/2026 | 6.63 USD |
| 6/11/2026 | 6.67 USD |
| 6/10/2026 | 6.70 USD |
| 6/9/2026 | 6.87 USD |
| 6/8/2026 | 6.59 USD |
| 6/5/2026 | 6.71 USD |
| 6/4/2026 | 6.80 USD |
| 6/3/2026 | 6.55 USD |
| 6/2/2026 | 6.47 USD |
| 6/1/2026 | 6.72 USD |
| 5/29/2026 | 6.85 USD |
| 5/28/2026 | 6.88 USD |
| 5/27/2026 | 6.83 USD |
| 5/26/2026 | 6.73 USD |
| 5/25/2026 | 7.19 USD |
| 5/22/2026 | 6.84 USD |
| 5/21/2026 | 6.87 USD |
| 5/20/2026 | 6.79 USD |
| 5/19/2026 | 6.64 USD |
| 5/15/2026 | 6.84 USD |
| 5/14/2026 | 7.06 USD |
| 5/13/2026 | 7.10 USD |
| 5/12/2026 | 7.06 USD |
| 5/11/2026 | 7.20 USD |
| 5/8/2026 | 6.88 USD |
| 5/7/2026 | 7.12 USD |
| 5/6/2026 | 7.22 USD |
| 5/5/2026 | 7.21 USD |
| 5/4/2026 | 6.66 USD |
| 5/1/2026 | 6.86 USD |
| 4/30/2026 | 6.65 USD |
| 4/29/2026 | 6.53 USD |
| 4/28/2026 | 6.70 USD |
| 4/27/2026 | 6.77 USD |
| 4/24/2026 | 6.97 USD |
| 4/23/2026 | 6.82 USD |
| 4/22/2026 | 6.94 USD |
| 4/21/2026 | 6.82 USD |
| 4/20/2026 | 7.20 USD |
| 4/17/2026 | 6.66 USD |
| 4/16/2026 | 6.66 USD |
| 4/15/2026 | 6.50 USD |
| 4/14/2026 | 6.38 USD |
| 4/13/2026 | 6.21 USD |
| 4/10/2026 | 5.99 USD |
| 4/9/2026 | 6.64 USD |
| 4/8/2026 | 6.63 USD |
| 4/7/2026 | 6.47 USD |
| 4/6/2026 | 6.63 USD |
| 4/2/2026 | 6.48 USD |
| 4/1/2026 | 6.67 USD |
| 3/31/2026 | 6.50 USD |
| 3/30/2026 | 6.04 USD |
| 3/27/2026 | 6.26 USD |
| 3/26/2026 | 6.42 USD |
| 3/25/2026 | 5.87 USD |
| 3/24/2026 | 5.22 USD |
| 3/23/2026 | 5.37 USD |
| 3/20/2026 | 5.10 USD |
| 3/19/2026 | 5.15 USD |
| 3/18/2026 | 5.51 USD |
| 3/17/2026 | 5.86 USD |
| 3/16/2026 | 5.68 USD |
| 3/13/2026 | 5.51 USD |
| 3/12/2026 | 5.54 USD |
| 3/11/2026 | 5.54 USD |
| 3/10/2026 | 5.33 USD |
| 3/9/2026 | 5.16 USD |
| 3/6/2026 | 5.17 USD |
| 3/5/2026 | 7.30 USD |
| 3/4/2026 | 7.40 USD |
| 3/3/2026 | 7.32 USD |
| 3/2/2026 | 7.35 USD |
| 2/27/2026 | 7.54 USD |
| 2/26/2026 | 7.80 USD |
| 2/25/2026 | 7.39 USD |
| 2/24/2026 | 7.05 USD |
| 2/23/2026 | 7.00 USD |
| 2/20/2026 | 6.80 USD |
| 2/19/2026 | 6.88 USD |
| 2/18/2026 | 6.96 USD |
| 2/17/2026 | 6.67 USD |
| 2/13/2026 | 6.50 USD |
| 2/12/2026 | 6.21 USD |
| 2/11/2026 | 6.31 USD |
| 2/10/2026 | 6.29 USD |
| 2/9/2026 | 6.36 USD |
| 2/6/2026 | 6.40 USD |
| 2/5/2026 | 6.39 USD |
| 2/4/2026 | 6.76 USD |
| 2/3/2026 | 7.00 USD |
| 2/2/2026 | 7.75 USD |
| 1/30/2026 | 7.45 USD |
| 1/29/2026 | 7.24 USD |
| 1/28/2026 | 7.48 USD |
| 1/27/2026 | 7.63 USD |
| 1/26/2026 | 7.74 USD |
| 1/23/2026 | 7.87 USD |
| 1/22/2026 | 7.82 USD |
| 1/21/2026 | 8.01 USD |
| 1/20/2026 | 7.89 USD |
| 1/19/2026 | 8.32 USD |
| 1/16/2026 | 8.48 USD |
| 1/15/2026 | 8.42 USD |
| 1/14/2026 | 7.83 USD |
| 1/13/2026 | 8.47 USD |
| 1/12/2026 | 8.84 USD |
| 1/9/2026 | 8.55 USD |
| 1/8/2026 | 8.60 USD |
| 1/7/2026 | 8.23 USD |
| 1/6/2026 | 7.79 USD |
| 1/5/2026 | 7.78 USD |
| 1/2/2026 | 7.70 USD |
| 12/31/2025 | 7.86 USD |
| 12/30/2025 | 7.24 USD |
| 12/29/2025 | 7.26 USD |
| 12/24/2025 | 7.48 USD |
| 12/23/2025 | 7.33 USD |
| 12/22/2025 | 7.32 USD |
| 12/19/2025 | 7.64 USD |
| 12/18/2025 | 7.73 USD |
| 12/17/2025 | 7.57 USD |
| 12/16/2025 | 7.43 USD |
| 12/15/2025 | 7.70 USD |
| 12/12/2025 | 7.28 USD |
| 12/11/2025 | 7.48 USD |
| 12/10/2025 | 7.23 USD |
| 12/9/2025 | 7.12 USD |
| 12/8/2025 | 6.79 USD |
| 12/5/2025 | 6.62 USD |
| 12/4/2025 | 6.80 USD |
| 12/3/2025 | 7.02 USD |
| 12/2/2025 | 6.24 USD |
| 12/1/2025 | 6.53 USD |
| 11/28/2025 | 6.63 USD |
| 11/27/2025 | 6.70 USD |
| 11/26/2025 | 6.57 USD |
| 11/25/2025 | 6.64 USD |
| 11/24/2025 | 6.24 USD |
| 11/21/2025 | 6.11 USD |
| 11/20/2025 | 5.97 USD |
| 11/19/2025 | 6.18 USD |
| 11/18/2025 | 6.26 USD |
| 11/17/2025 | 6.61 USD |
| 11/14/2025 | 6.88 USD |
| 11/13/2025 | 6.60 USD |
| 11/12/2025 | 6.61 USD |
| 11/11/2025 | 6.61 USD |
| 11/10/2025 | 6.11 USD |
| 11/7/2025 | 6.11 USD |
| 11/6/2025 | 6.06 USD |
| 11/5/2025 | 6.10 USD |
| 11/4/2025 | 6.10 USD |
| 11/3/2025 | 6.04 USD |
| 10/31/2025 | 6.10 USD |
| 10/30/2025 | 6.28 USD |
| 10/29/2025 | 6.26 USD |
| 10/28/2025 | 6.32 USD |
| 10/27/2025 | 5.67 USD |
| 10/24/2025 | 5.62 USD |
| 10/23/2025 | 5.40 USD |
| 10/22/2025 | 5.57 USD |
| 10/21/2025 | 5.99 USD |
| 10/20/2025 | 5.95 USD |
| 10/17/2025 | 5.57 USD |
| 10/16/2025 | 5.65 USD |
| 10/15/2025 | 5.84 USD |
| 10/14/2025 | 5.90 USD |
| 10/10/2025 | 5.84 USD |
| 10/9/2025 | 6.61 USD |
| 10/8/2025 | 6.75 USD |
| 10/7/2025 | 6.42 USD |
| 10/6/2025 | 5.80 USD |
| 10/3/2025 | 5.76 USD |
| 10/2/2025 | 5.45 USD |
| 10/1/2025 | 4.94 USD |
| 9/30/2025 | 4.96 USD |
| 9/29/2025 | 5.18 USD |
| 9/26/2025 | 5.34 USD |
| 9/25/2025 | 5.26 USD |
| 9/24/2025 | 5.46 USD |
| 9/23/2025 | 5.11 USD |
| 9/22/2025 | 4.34 USD |
| 9/19/2025 | 4.35 USD |
| 9/18/2025 | 4.17 USD |
| 9/17/2025 | 3.96 USD |
| 9/16/2025 | 4.04 USD |
| 9/15/2025 | 4.13 USD |
| 9/12/2025 | 4.05 USD |
| 9/11/2025 | 4.02 USD |
| 9/10/2025 | 3.91 USD |
| 9/9/2025 | 4.13 USD |
| 9/8/2025 | 4.11 USD |
| 9/5/2025 | 4.20 USD |
| 9/4/2025 | 4.40 USD |
| 9/3/2025 | 4.43 USD |
| 9/2/2025 | 4.52 USD |
| 8/29/2025 | 4.50 USD |
| 8/28/2025 | 4.53 USD |
| 8/27/2025 | 4.54 USD |
| 8/26/2025 | 4.54 USD |
| 8/25/2025 | 4.76 USD |
| 8/22/2025 | 4.80 USD |
| 8/21/2025 | 4.77 USD |
| 8/20/2025 | 4.67 USD |
| 8/19/2025 | 4.65 USD |
| 8/18/2025 | 4.83 USD |
| 8/15/2025 | 4.35 USD |
Profound Medical Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Profound Medical Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 3.00 | 2.00 | 4.00 | 7.00 | 6.00 | 6.00 | 7.00 | 10.00 | 17.00 | 25.00 | 43.00 | 72.00 | 105.00 | 139.00 | 333.00 |
| – | – | -33.33 | 100.00 | 75.00 | -14.29 | – | 16.67 | 42.86 | 70.00 | 47.06 | 72.00 | 67.44 | 45.83 | 32.38 | 139.57 |
| – | 33.33 | 350.00 | 50.00 | 42.86 | 33.33 | 50.00 | 57.14 | 70.00 | 70.00 | 70.00 | 70.00 | 70.00 | 70.00 | 70.00 | 70.00 |
| 7.00 | 1.00 | 7.00 | 2.00 | 3.00 | 2.00 | 3.00 | 4.00 | 7.00 | 11.90 | 17.50 | 30.10 | 50.40 | 73.50 | 97.30 | 233.10 |
| -11.00 | -13.00 | -15.00 | -14.00 | -18.00 | -30.00 | -29.00 | -28.00 | -33.00 | -17.00 | -25.00 | -43.00 | -72.00 | -105.00 | -139.00 | – |
| – | -433.33 | -750.00 | -350.00 | -257.14 | -500.00 | -483.33 | -400.00 | -330.00 | -100.00 | -100.00 | -100.00 | -100.00 | -100.00 | -100.00 | – |
| -12.00 | -14.00 | -16.00 | -15.00 | -21.00 | -30.00 | -28.00 | -28.00 | -27.00 | -33.00 | -20.00 | -18.00 | 9.00 | 17.00 | 26.00 | 66.00 |
| – | 16.67 | 14.29 | -6.25 | 40.00 | 42.86 | -6.67 | – | -3.57 | 22.22 | -39.39 | -10.00 | -150.00 | 88.89 | 52.94 | 153.85 |
| 4.15 | 6.14 | 10.04 | 11.10 | 17.29 | 20.46 | 20.83 | 21.18 | 24.77 | 24.77 | 24.77 | 24.77 | 24.77 | 24.77 | 24.77 | 24.77 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Profound Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Profound Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Profound Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Profound Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Profound Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Profound Medical stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Profound Medical Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Profound Medical business model & stock analysis
Profound Medical SWOT Analysis
Strengths
Profound Medical Corp has a strong track record of technological innovation in the field of medical devices, particularly in the area of non-invasive surgical technologies. This has enabled the company to develop groundbreaking products that have revolutionized patient care.
The company possesses an extensive intellectual property portfolio, including patents, trademarks, and trade secrets, which provides a significant competitive advantage in the market. This helps protect their innovative technologies from being replicated by competitors.
Profound Medical Corp is led by a highly experienced management team with deep industry knowledge and expertise. Their collective leadership skills and strategic vision have played a crucial role in driving the company's growth and success.
Weaknesses
Despite their innovative products, Profound Medical Corp faces the challenge of limited market reach, primarily due to the niche nature of their target market. This may impact their revenue potential and hinder their ability to scale up rapidly.
Developing advanced medical technologies requires substantial investment in research and development. Profound Medical Corp may face challenges in consistently funding these activities, especially during economic downturns, which could impact their ability to stay at the forefront of innovation.
As a medical device company, Profound Medical Corp heavily relies on regulatory approvals from various authorities. Any delays or difficulties in obtaining necessary approvals can significantly impact their product launch timelines and overall market competitiveness.
Opportunities
The market for non-invasive surgical technologies is on the rise, driven by increasing patient preference for minimally invasive procedures and improvements in healthcare infrastructure. Profound Medical Corp can capitalize on this trend by expanding their product offerings and capturing a larger market share.
With their innovative products, Profound Medical Corp can enter emerging markets where there is a growing need for advanced medical technologies. These markets offer significant growth potential and can diversify the company's revenue streams.
Forming strategic partnerships and collaborations with healthcare organizations, research institutions, and key opinion leaders can provide Profound Medical Corp with access to expertise, resources, and a wider customer base. This can enhance their market presence and accelerate product development.
Threats
The medical device industry is highly competitive, with numerous established players and new entrants vying for market share. Profound Medical Corp faces the risk of intense competition, which may result in price pressure, reduced profit margins, and the need for continuous innovation.
Strict regulations and compliance requirements in the healthcare industry pose challenges to Profound Medical Corp. The company needs to ensure full compliance with regulatory standards and adapt quickly to any changes, as non-compliance can lead to penalties, reputational damage, and potential product recalls.
The medical device industry is characterized by rapid technological advancements. There is a risk that Profound Medical Corp's innovative products may become obsolete if they fail to keep up with emerging technologies. The company needs to invest in research and development to stay at the forefront of industry trends.
Profound Medical Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Profound Medical historical P/E ratio, EBIT multiple, and P/S ratio
Profound Medical annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Profound Medical shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Profound Medical stock splits
Current Profound Medical forecasts and price targets in August 2026
Analyst Price Targets 2026Profound Medical Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 1/7/2026 | Maintained | Buy | – | |
| 4/23/2025 | Maintained | Buy | – | |
| 7/16/2024 | Upgrade | HoldBuy | – | |
| 3/11/2024 | Maintained | Buy | – | |
| 3/8/2024 | Maintained | Hold | – | |
| 1/4/2024 | Maintained | Buy | – | |
| 8/4/2023 | Downgrade | Strong BuyOutperform | 74 | |
| 5/11/2023 | Maintained | Outperform | 60 | |
| 5/11/2023 | Maintained | Buy | – | |
| 3/21/2023 | Downgrade | BuyEqual Weight | 47 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Profound Medical Earnings Calls
Profound Medical Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/8/2024 | -0.32USD | - | 2.12 MUSD | - | 2024 Q1 |
| 3/5/2024 | -0.35USD | - | 2.11 MUSD | - | 2023 Q4 |
| 8/2/2023 | -0.37USD | - | 3.38 MUSD | - | 2023 Q2 |
| 5/8/2023 | -0.37USD | - | 2.87 MUSD | - | 2023 Q1 |
| 3/1/2023 | -0.37USD | - | 3.19 MUSD | - | 2022 Q4 |
| 11/3/2022 | -0.37USD | - | 2.23 MUSD | - | 2022 Q3 |
| 8/4/2022 | -0.40USD | - | 1.83 MUSD | - | 2022 Q2 |
| 5/9/2022 | -0.46USD | - | 2.20 MUSD | - | 2022 Q1 |
| 3/3/2022 | -0.34USD | - | 2.61 MUSD | - | 2021 Q4 |
| 11/4/2021 | -0.27USD | - | 3.91 MUSD | - | 2021 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Profound Medical stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Profound Medical shareholder structure
| % | Name |
|---|---|
7.61139% | |
7.06593% | |
4.86261% | |
3.62065% | |
3.48333% | |
3.39446% |
Profound Medical Beneficial Ownership Filings (SEC 13D/G)
Profound Medical Executives and Management Board
10 members · avg. age 60 · 20 % women
Dr. Arun Menawat (70)
Chairman of the Board, Chief Executive Officer · since 2015
2.46 M USD
Management
Dr. Mathieu Burtnyk (43)
President
Mr. Rashed Dewan (57)
Chief Financial Officer
Mr. Tom Tamberrino (45)
Chief Commercial Officer
Mr. Stephen Kilmer
Investor Relations
Board of Directors
Mr. Brian Ellacott (68)
Non-Executive Independent Director
Dr. Arthur Rosenthal (78)
Non-Executive Independent Director
Ms. Murielle Lortie (56)
Non-Executive Independent Director
Dr. Cynthia Lavoie (58)
Non-Executive Independent Director
Mr. Kris Shah (64)
Non-Executive Independent Director
Frequently asked questions about Profound Medical
Profound Medical Corp is a medical technology company specializing in the development of real-time magnetic resonance imaging (MRI) guided ablation devices for the treatment of diseases such as prostate cancer. The company's business model revolves around the creation and commercialization of innovative solutions that enable precise and personalized ablation procedures. Profound's devices utilize thermal energy to heat and destroy targeted tissue while providing real-time feedback to clinicians for enhanced safety and efficacy. By leveraging cutting-edge MRI technology, Profound Medical Corp aims to optimize patient outcomes in the field of minimally invasive therapies, positioning itself as a leader in the evolving landscape of image-guided treatments.
Profound Medical Corp is primarily active in the medical industry.
The main competitors of Profound Medical Corp in the market include SonaCare Medical, Inc., EDAP TMS S.A., and Exact Imaging Inc.
Profound Medical Corp is a prominent medical technology company that focuses on developing and commercializing innovative treatments for prostate cancer. Established in 2008, Profound Medical has made significant strides in the field of image-guided therapy. Their flagship product, TULSA-PRO, utilizes MRI and ultrasound technology to deliver precise and personalized thermal ablation treatments, effectively destroying targeted prostate tissue while minimizing damage to surrounding areas. This revolutionary approach provides patients with a non-invasive or minimally invasive option, reducing side effects and improving outcomes. Profound Medical Corp continues to advance the field of prostate cancer treatment, offering hope to patients worldwide.
Profound Medical Corp, a leading medical device company, has achieved several significant milestones. Firstly, they received FDA approval for their revolutionary TULSA-PRO system, which offers non-invasive treatment for prostate cancer. This milestone has positioned Profound Medical Corp as a game-changer in the field of prostate cancer treatments. Additionally, the company successfully completed a clinical trial, showcasing the TULSA-PRO system's remarkable efficacy and safety profile. Furthermore, Profound Medical Corp expanded its market reach by establishing strategic partnerships with renowned cancer centers and leading healthcare providers. Through continuous innovation and collaboration, Profound Medical Corp has cemented its position as a trailblazer in the fight against prostate cancer.
Profound Medical Corp primarily operates in the United States, Canada, and Europe.
Profound Medical Corp is committed to transforming the lives of patients with minimally invasive, incision-free therapies for the treatment of prostate disease. Their corporate philosophy revolves around innovation, patient-centricity, and a dedication to advancing medical technologies. By leveraging their cutting-edge TULSA-PRO® system, Profound Medical Corp aims to provide precise and personalized treatments, reducing potential side effects while enhancing treatment outcomes. With a focus on research and development, they strive to continuously improve their therapeutic offerings and expand their reach globally. Profound Medical Corp's values encompass integrity, collaboration, and a commitment to revolutionizing healthcare through their transformative solutions.
Analysts currently set an average price target of 11.17 USD for the Profound Medical stock (median: 11.17 USD), implying +68.4 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Profound Medical stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Profound Medical to generate revenue of 25.88 M USD and earnings per share of -0.84 USD.
Converted at the current exchange rate, the Profound Medical share trades at 5.75 EUR (6.63 USD).
The Profound Medical share (PRN.TO) is listed on 2 stock exchanges, including: NASDAQ (PROF), Toronto (PRN.TO).
Profound Medical Corp is a leading company in the development of innovative medical technologies for the treatment of prostate cancer. The company's business model is based on the development and marketing of its advanced therapy systems for the treatment of localized prostate cancer. The divisions of Profound Medical Corp include research and development, marketing and distribution of medical devices. The company focuses on developing medical products that meet the patients' need for state-of-the-art, minimally invasive treatments. The devices of Profound Medical Corp are targeted towards the target group of urologists and radiation therapists. The main product of Profound Medical Corp is the TULSA-PRO® System, an innovative HIFU (High-Intensity Focused Ultrasound) system that enables the minimally invasive treatment of localized prostate cancer. The technology is based on an ultrasound device that destroys the diseased tissue in the prostate using sound waves without damaging the surrounding tissue. The minimally invasive procedure is performed on an outpatient basis and minimizes the risk of complications and side effects. The TULSA-PRO® System offers many advantages compared to other conventional treatment methods. For example, it is gentler and faster than radiation therapy or surgery and has a better success rate than the use of chemotherapy or hormonal therapies. In addition, the TULSA-PRO® System is approved by the FDA, the American Food and Drug Administration, and CE-marked. The company also provides comprehensive training and technical support for users of the TULSA-PRO® System. Therefore, consulting, device management, and continuous maintenance are further services offered by Profound Medical Corp. In the course of its business activities, the company strives for close cooperation with leading research institutions and specialists in the field of cancer treatment. The goal is to develop innovative technologies that improve the diagnosis and treatment of prostate cancer and increase the quality of life of affected patients. In conclusion, the business model of Profound Medical Corp is focused on the needs of patients and their doctors. With the development and marketing of innovative medical devices, the company offers advanced technology that enables minimally invasive treatment of prostate cancer. Through collaboration with leading research institutions, Profound Medical Corp further expands its expertise in the field of cancer treatment.
The expected revenue of Profound Medical is 25.88 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Profound Medical is -20.72 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Profound Medical is currently -7.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Profound Medical stock.
The price-to-sales ratio (P/S) of Profound Medical is currently 6.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Profound Medical stock.
The Eulerpool Quality Score for Profound Medical is 4/10.
The ISIN of Profound Medical is CA74319B5027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Profound Medical is PRN.TO. The ticker symbol is used to trade Profound Medical shares on the stock exchange.
Profound Medical paid dividends every year for the past 0 years.
Profound Medical is assigned to the 'Health' sector.
The dividends of Profound Medical are distributed in USD.
Profound Medical stock
Profound Medical Peer Group
Profound Medical Ticker
Profound Medical FIGI
All fundamentals and in-depth analysis of Profound Medical
Our stock analysis for Profound Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Profound Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.